Compare TG Therapeutics Inc (TGTX) vs Vanguard Total International Stock Index Fund ETF (VXUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Vanguard Total International Stock Index Fund ETF — how do they compare? TG Therapeutics Inc trades at $54.85 (market cap $8.16B), while Vanguard Total International Stock Index Fund ETF trades at $84.72 (market cap $665.70B). The key difference: Vanguard Total International Stock Index Fund ETF is far larger — about 81.6× TG Therapeutics Inc's market cap, and Vanguard Total International Stock Index Fund ETF is more actively traded (4,864,744 versus 1,735,121). Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Vanguard Total International Stock Index Fund ETF for 55 Days on average.
| TGTX | VXUS | |
|---|---|---|
Market Cap | $8.16B | $665.70B |
Volume | 1,735,121 | 4,864,744 |
Sector | Health | Sector/Thematic |
52-Week High | $59.06 | $88.41 |
52-Week Low | $26.94 | $72.17 |
Typical Hold Time | 16 Days | 55 Days |
Enterprise Value | $8.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
VXUS trades at $84.67, down 0.13% with a bearish technical signal from moving averages and oscillators. The ETF provides diversified international stock exposure excluding U.S. markets, with recent institutional buying interest from firms like QRG Capital and Baird Financial. Support levels cluster around $83-84 while resistance sits at $85.
The outlook remains cautious given technical bearishness, though long-term diversification benefits and institutional accumulation provide support. Key risks include foreign market volatility and currency fluctuations, while the absence of U.S. exposure offers portfolio hedging advantages during domestic downturns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Vanguard Total International Stock Index Fund ETF
VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.
Read more on VXUS →
